Sandy Liebhard

Sandy A. Liebhard, a founding partner at Bernstein Liebhard LLP, has successfully represented plaintiffs in complex litigations for more than 20 years. As dedicated consumer advocates, Mr. Liebhard and his fellow attorneys have taken on some of the largest corporate interest in the nation in cases involving dangerous pharmaceuticals, faulty medical devices and defective consumer products. As an author for RXInuryHelp.com, Mr. Liebhard has written extensively on the litigation involving proton pump inhibitors (Nexium, Prilosec, PrevAcid, etc.) and kidney injuries; Risperdal and gynecomastia; the Bair Hugger forced air warming blanket; talcum powder and ovarian cancer; transvaginal mesh; power morcellators; defective hip implants; and more.

Mr. Liebhard is a 1988 graduate of Brooklyn Law School. He is admitted to the Bar of the State of New York, as well as the United States District Courts for the Southern and Eastern Districts of New York.


European Regulator Issues Xeljanz Warning After Study Sees Pulmonary Embolism, Death Risk with Higher Dose

Regulators in Europe have issued a new Xeljanz warning, after data from an ongoing study suggested pulmonary embolism and death occurred more frequently among patients taking a higher dose of the medication. What is Xeljanz? Xeljanz is a twice-daily tablet … Continue reading

As One Johnson & Johnson Talcum Powder Lawsuit Trial Nears its End, Another Begins

A long-running mesothelioma trial involving Johnson & Johnson’s Baby Powder is nearing its end game in New Jersey’s Middlesex County Superior Court, as the parties prepare to present closing arguments later today. At the same time, a California jury will … Continue reading

Connecticut Veteran Joins Growing Litigation Over 3M Combat Arms Earplugs

A Connecticut man has become one of the most recent military veterans to sue the 3M Company over allegedly defective Combat Arms Earplugs. According to a complaint filed in the U.S. District Court, District of Connecticut, on March 19th, Jonathan … Continue reading

Monsanto Roundup Jury Hears Misconduct Claims, as Federal Trial Enters 2nd Phase

A closely-watched trial involving Roundup weed killer and its alleged potential to cause cancer entered its second phase Wednesday, when jurors in San Francisco federal court were told of Monsanto’s alleged efforts to manipulate science and conceal the health risks … Continue reading

Mounting Breast Implant Illness Reports Prompt Renewed Concern at FDA

The U.S. Food & Drug Administration (FDA) is taking another look at breast implant illness, amid mounting reports tying the popular devices to joint pain, severe fatigue, and other serious health problems. Breast Implant Illness Reports Not Taken Seriously Roughly … Continue reading

FDA Approves New Generic Valsartan Amid Continuing Blood Pressure Drug Recalls

In a bid to alleviate shortages stemming from ongoing blood pressure drug recalls, the U.S. Food & Drug Administration (FDA) has approved a new generic version of valsartan. Blood Pressure Drug Recalls Impact 20+ Countries Valsartan is the generic name … Continue reading

Clergy Sexual Abuse Lawsuit Claims West Virginia Diocese Knowingly Employed Predatory Priest

The West Virginia Attorney General has sued the Roman Catholic Diocese of Wheeling-Charleston a for knowingly employing child sexual abusers. This latest clergy sexual abuse lawsuit was filed on Tuesday in Wood County Circuit, and accuses the diocese of violating West … Continue reading

Roundup Cancer Jury Finds for Plaintiff After 1st Phase of Federal Trial

A federal jury has found that Monsanto’s Roundup weed killer was a “substantial factor” in a California man’s cancer, concluding the first phase of a closely watched bellwether trial. Roundup Lawsuit Blamed Glyphosate for Cancer Edwin Hardeman, 77, had use … Continue reading

European Regulator Investigating Xeljanz Pulmonary Embolism Risk

Regulators in Europe have launched a safety review of Xeljanz, amid concern that patients might be more likely to suffer a pulmonary embolism or die while taking a higher dose of the medication. The European Xeljanz review was announced on … Continue reading

New Technology Could Allow MS Patients to Avoid Gadolinium-Based MRI Scans

The growing availability of new technology could allow doctors to monitor disease progression in Multiple Sclerosis (MS) patients without using  gadolinium-based MRI contrast agents. New Tech Improved Images on Gadolinium-Free MRIs People with relapsing MS generally undergo MRI brain scans with … Continue reading

Follow Us

RXInjuryHelp.com on Google+  RXInjuryHelp.com on Facebook  RXInjuryHelp.com on LinkedIn  RXInjuryHelp.com on Twitter  RXInjuryHelp.com on YouTube  RXInjuryHelp.com on Pinterest

Skip to content